Linke Michael J, Ashbaugh Alan A, Koch Judith V, Levin Linda, Tanaka Reiko, Walzer Peter D
Research Service, Department of Veterans Affairs Medical Center, Cincinnati, Ohio 45220, USA.
J Eukaryot Microbiol. 2009 Jan-Feb;56(1):58-65. doi: 10.1111/j.1550-7408.2008.00363.x.
We examined the effects of surfactant protein A (SP-A), a collectin, on the interaction of Pneumocystis murina with its host at the beginning, early to middle, and late stages of infection. Pneumocystis murina from SP-A wild-type (WT) mice inoculated intractracheally into WT mice (WT(S)-WT(R)) adhered well to alveolar macrophages, whereas organisms from SP-A knockout (KO) mice inoculated into KO mice (KO(S)-KO(R)) did not. Substitution of WT mice as the source of organisms (WT(S)-KO(R)) or recipient host macrophages (KO(S)-WT(R)) restored adherence to that found with WT(S)-WT(R) mice. In contrast, when immunosuppressed KO and WT mice were inoculated with P. murina from a homologous source (KO(S)-KO(R), WT(S)-WT(R)) or heterologous source (WT(S)-KO(R), KO(S)-WT(R)) and followed sequentially, WT(S)-KO(R) mice had the highest levels of infection at weeks 3 and 4; these mice also had the highest levels of the chemokine macrophage inflammatory protein-2 and neutrophils in lavage fluid at week 3. Surfactant protein-A administered to immunosuppressed KO(S)-KO(R) mice with Pneumocystis pneumonia for 8 wk as a therapeutic agent failed to lower the organism burden. We conclude that SP-A can correct the host immune defect in the beginning of P. murina infection, but not in the middle or late stages of the infection.
我们研究了凝集素表面活性蛋白A(SP-A)在感染初期、早期至中期以及晚期对鼠肺孢子菌与其宿主相互作用的影响。将来自经气管内接种到野生型(WT)小鼠体内的SP-A野生型(WT)小鼠的鼠肺孢子菌(WT(S)-WT(R))与肺泡巨噬细胞的黏附良好,而接种到基因敲除(KO)小鼠体内的来自SP-A基因敲除(KO)小鼠的病原体(KO(S)-KO(R))则不然。用WT小鼠作为病原体来源(WT(S)-KO(R))或受体宿主巨噬细胞(KO(S)-WT(R))进行替换,可使黏附恢复到WT(S)-WT(R)小鼠的水平。相比之下,当免疫抑制的KO和WT小鼠接种来自同源来源(KO(S)-KO(R),WT(S)-WT(R))或异源来源(WT(S)-KO(R),KO(S)-WT(R))的鼠肺孢子菌并进行连续观察时,WT(S)-KO(R)小鼠在第3周和第4周的感染水平最高;这些小鼠在第3周时灌洗液中的趋化因子巨噬细胞炎性蛋白-2和中性粒细胞水平也最高。作为治疗剂,对患有肺孢子菌肺炎的免疫抑制KO(S)-KO(R)小鼠给予表面活性蛋白A 8周,未能降低病原体负荷。我们得出结论,SP-A可以在鼠肺孢子菌感染初期纠正宿主免疫缺陷,但在感染的中期或晚期则不能。